key: cord-0855001-nv8abkud
authors: Kim, J.E.; Lee, H.; Paik, S.S.; Moon, J.‐Y.; Yoon, H.J.; Kim, S.‐H.
title: Delayed cutaneous reaction to ChAdOx1 nCoV‐19 vaccine: Is it an ‘AstraZeneca arm’?
date: 2021-07-12
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17476
sha: a830d7888a107bf40350f6368ea850b19d7fae6e
doc_id: 855001
cord_uid: nv8abkud

Blumenthal et al.1 reported cases of delayed large local reaction to the mRNA-1273 Moderna COVID-19 vaccine, which was called the 'Moderna arm' for the first time. Intriguingly, this phenomenon was observed primarily in Moderna vaccine, but rarely reported in BNT162b2 COVID-19 vaccine by Pfizer-BioNTech.2-4 Because the reports were limited to mRNA vaccines, a delayed type hypersensitivity reaction to the excipient polyethylene glycol (PEG) in both mRNA vaccines was suggested as one potential etiology.4,5.

Blumenthal et al. 1 reported cases of delayed large local reaction to the mRNA-1273 Moderna COVID-19 vaccine, which was called the 'Moderna arm' for the first time. Intriguingly, this phenomenon was observed primarily in Moderna vaccine but rarely reported in BNT162b2 COVID-19 vaccine by Pfizer-BioNTech. [2] [3] [4] Because the reports were limited to mRNA vaccines, a delayed-type hypersensitivity reaction to the excipient polyethylene glycol (PEG) in both mRNA vaccines was suggested as one potential aetiology. 4, 5 Unlikely these mRNA vaccines, ChAdOx1 nCoV-19 (AZD1222) is a replication-defective chimpanzee adenovirus-vectored vaccine, and it includes polysorbate 80 as an excipient. 6 Recently, we have observed delayed cutaneous reactions around the injection site of the ChAdOx1 nCoV-19 vaccine. We report four cases with such reactions that developed at least three days (range, Day 4-17) after the first dose of vaccination (Table 1 ). All the patients were female healthcare workers (1 physician, 2 nurses and 1 laboratory technician) at our university hospitals and were ethnically Korean. They did not have a previous history of hypersensitivity reactions to drugs or any vaccine. Only one patient had allergic rhinitis but did not require regular medication. Routine blood tests including complete blood cell counts, C-reactive protein and serum IgE were unremarkable. All patients had a large delayed skin reaction that started with erythematous swelling (Fig. 1a-d) , and three developed systemic symptoms including fever, chill and myalgia from the day of vaccination and that resolved before the delayed skin reactions. Thus, at the development of delayed local skin reactions, none of the patients experienced concurrent systemic symptoms. The delayed skin lesions resolved after short-term treatment, such as oral antihistamines or topical or oral corticosteroids, while the duration of skin reaction varied from 4 to 18 days. Skin biopsy from three patients showed superficial perivascular and perifollicular lymphocytic infiltration with sparse eosinophils (Fig. 1e-k) . These findings suggest that the delayed local cutaneous reactions are mediated by hypersensitivity mechanisms. However, the exact pathophysiological mechanism remains unclear if they are true hypersensitivity reactions. One reason for this controversy is that the skin tests (patch, prick, and intradermal test) of the patient who was injected BNT162b2 vaccine were all negative. 2 In the aspect of hypersensitivity reaction, unlike PEG, polysorbate 80 in ChAdOx1 nCoV-19 vaccine has been used in other vaccines before, it is still unclear which antigen in the vaccine caused these reactions.

Our report suggests that the delayed local cutaneous reactions to the COVID-19 vaccines are not vaccine-specific, since both mRNA vaccine and viral-vector vaccine showed such reactions. Before implementing a mass vaccination campaign with various COVID-19 vaccines, clinicians should be aware of the possible (e-g) Skin biopsy specimen from patient 4 shows superficial perivascular and perifollicular lymphocytic infiltration and some eosinophils. Neutrophils are present inside dilated small vessels. Immunohistochemistry reveals mainly CD3 + T cells with sparse exocytosis (h) and few CD20 + B cells (i). There is a mixed population of CD4 + (j) and CD8 + (k) cells, but CD4 + is predominant. These findings are consistent with a delayed hypersensitivity reaction (e: H&E 940, f: H&E 9200, g: H&E 9400, h: CD3 940, i: CD20 940, j: CD4 940, k: CD8 940).

'COVID-arm' to avoid unnecessary tests or treatment. While the Centers for Disease Control and Prevention reported that patients who experienced delayed cutaneous reactions to the first dose of COVID-19 vaccine could be safely vaccinated with the second dose, 7 more data are required to understand and manage the 'COVID-arm' to various COVID-19 vaccines.

Jeong Eun Kim, Hyun Lee, Seung Sam Paik, Ji-Yong Moon, Ho Joo Yoon and Sang-Heon Kim declare to have no conflict of interest.

None.

Yes (Number HYUH 2021-03-052).

Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2

Delayed large local reactions to mRNA vaccines

Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registrybased study of 414 cases

Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from North-East Italy

Safety and efficacy of the ChA-dOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

The patients in this manuscript have given written informed consent to the publication of their case details. This research was supported by a grant from the Korean Academy of Asthma, Allergy and Clinical Immunology.